Suven Pharmaceuticals saw its shares rise by 3% following Goldman Sachs’ bullish outlook, as the global brokerage initiated coverage with a ‘Buy’ rating and a target price of ₹1,350. The firm expects a strong growth trajectory for Suven, driven by structural expansion and a sharp recovery starting FY26.
Goldman Sachs highlighted the company’s robust pipeline and strategic acquisitions as key drivers of this anticipated performance. The continued momentum in key drugs like Empagliflozin, Finerenone, and Antibody Drug Conjugates is expected to significantly boost revenue. Additionally, upcoming drug and indication approvals, including promising candidates such as Zongertinib and Nerandomilast, are likely to add further value.
The successful integration of recent acquisitions—Cohance, Sapala, and NJ Bio—is expected to strengthen operational synergies and broaden Suven’s capabilities in the contract research and manufacturing services (CRAMS) space. Furthermore, a broader macroeconomic recovery in the agrochemical sector is anticipated to support overall demand and growth.
Goldman projects that Suven Pharma’s combined entity could achieve over 20% compound annual EBITDA growth in the medium term. This places the company among the top growth picks in the brokerage’s India healthcare coverage.
Suven Pharmaceuticals shares opened at ₹1,101.90 today, reaching a high of ₹1,107.00 and a low of ₹1,073.60. The stock remains well below its 52-week high of ₹1,360.00 but significantly above its 52-week low of ₹598.00.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
